HLB Co Ltd is a Korea-based company mainly engaged in the development of biopharmaceutical products. The Company operates its business through three segments. The Bio and Healthcare segment is engaged in the development of biopharmaceuticals and the manufacture and sale of diagnostic, medical and healthcare products. The Composite Materials segment is engaged in the manufacture, repair and installation of lifeboats, pipes and other composite material products. The Media Commerce segment is engaged in media commerce-related operations.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

08-30	HLB Therapeutics Co.,Ltd. announced that it has received KRW 11.1810349 billion in funding from HLB Co., Ltd.	CI
08-18	HLB Co., Ltd. announced that it has received KRW 30 billion in funding from BNK Securities Co.,Ltd.	CI

Market Cap	4,181B 3.12B 3.12B 2.69B 2.54B 2.31B 4.33B 298B 4.35B 30.22B 11.62B 152B 11.71B 11.46B 479B	P/E 2024	-104x	P/E 2025	-30.2x
Enterprise Value	4,458B 3.33B 3.33B 2.87B 2.71B 2.46B 4.61B 318B 4.64B 32.22B 12.39B 162B 12.49B 12.22B 511B	EV / Sales 2024	142x	EV / Sales 2025	82.7x
Free-Float	90.62%	Yield 2024 *	-	Yield 2025	-

08-30	HLB Therapeutics Co.,Ltd. announced that it has received KRW 11.1810349 billion in funding from HLB Co., Ltd.	CI
08-18	HLB Co., Ltd. announced that it has received KRW 30 billion in funding from BNK Securities Co.,Ltd.	CI
08-14	HLB Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-05	HLB Therapeutics Co.,Ltd.has announced that it expects to receive KRW 11,181,034,920 from HLB Co., Ltd.	CI
08-05	HLB Co., Ltd. announced that it expects to receive KRW 30 billion in funding from BNK Securities Co.,Ltd. and other investors	CI
07-10	Elevar-Hengrui hit with third FDA rejection for liver cancer therapy over manufacturing concerns	RE
05-15	HLB Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Honliv Healthcare Management Group Company Limited Delays Earnings Results Release for the Fiscal Year Ended December 31, 2025	CI
04-14	HLB Co., Ltd. announced that it has received KRW 25 billion in funding from Hanyang Securities Co. Ltd., Mirae Asset Securities Co., Ltd., BNK Asset Management Co., Ltd., Cloud IB Investment Co., Ltd.	CI
04-06	HLB Co., Ltd. announced that it expects to receive KRW 25 billion in funding from Hanyang Securities Co. Ltd., Mirae Asset Securities Co., Ltd., BNK Asset Management Co., Ltd., Cloud IB Investment Co., Ltd and other investor.	CI
03-23	HLB Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-30	Elevar Therapeutics' NDA resubmission for rivoceranib with camrelizumab accepted by FDA	RE
12-30	HLB Co., Ltd. completed the acquisition of HLB SCIENCE Inc. from HLB GLOBAL Co., Ltd., HLB bioStep Co.,Ltd., HLB Life Science Co., Ltd., Yoon Jong-seon and others.	CI

23-09-04	Hessische Landesbahn weiter auf Wachstumskurs
23-08-10	USA: ouragans et maladie font grimper le cours du jus d'orange à un record
23-05-04	Eisenbahngewerkschaft sieht in Verhandlungen mit DB-Konkurrenten "Bewegung"
23-02-02	USA: record pour le prix du jus d'orange, mauvaises récoltes

Manager	Title	Age	Since
Hong-Cheol Kim CEO	Chief Executive Officer	61	2026-03-30
Dong-Gun Kim PSD	President	64	2024-03-28
Yong-Hae Han PRN	Corporate Officer/Principal	64	2025-03-30

HLB Inc Stock Korea S.E.

Stocks

Medical Equipment, Supplies & Distribution

Valuation : HLB Inc

Latest news : HLB Inc

News in other languages : HLB Inc

Managers and Directors : HLB Inc

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Director	Title	Age	Since
Yang-Gon Jin CHM	Chairman	60	-
Dong-gi Shin BRD	Director/Board Member	70	2024-03-28
In-bae Seol BRD	Director/Board Member	63	2024-03-28

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABBOTT LABORATORIES	-1.36%	-5.89%	-23.14%	-0.49%	176B
MEDTRONIC PLC	-0.72%	-3.41%	-3.49%	+11.74%	116B
CENCORA, INC.	+0.19%	-2.83%	+6.20%	+80.93%	61.36B
HOYA CORPORATION	-1.92%	-6.01%	+8.80%	+41.11%	49.42B
BECTON, DICKINSON AND COMPANY	+0.81%	-3.73%	-6.67%	-33.43%	48.44B
DEXCOM, INC.	-1.75%	-5.54%	+9.25%	-22.61%	31.33B
MEDLINE INC.	+0.43%	-11.10%	-	-	28.56B
WEST PHARMACEUTICAL SERVICES, INC.	+0.58%	+1.84%	+31.28%	-12.82%	24.37B
TERUMO CORPORATION	+0.49%	-7.65%	-12.44%	+4.86%	21.57B
Average	-0.36%	-5.08%	+1.22%	+8.66%	61.98B
Weighted average by Cap.	-0.69%	-4.90%	-6.07%	+10.85%

	2024	2025
Net sales	68.13B 50.82M 50.82M 43.79M 41.46M 37.58M 70.51M 4.86B 70.86M 492M 189M 2.47B 191M 187M 7.81B	84.17B 62.79M 62.79M 54.1M 51.23M 46.43M 87.11M 6B 87.55M 608M 234M 3.05B 236M 231M 9.64B
Net income	-91.98B -68.62M -68.62M -59.12M -55.98M -50.74M -95.19M -6.56B -95.68M -665M -256M -3.34B -258M -252M -10.54B	-221B -164M -164M -142M -134M -122M -228M -15.72B -229M -1.59B -613M -8B -618M -604M -25.26B
Net Debt	59.15B 44.13M 44.13M 38.02M 36M 32.63M 61.22M 4.22B 61.53M 428M 164M 2.14B 166M 162M 6.78B	277B 206M 206M 178M 168M 153M 286M 19.73B 288M 2B 769M 10.04B 775M 758M 31.71B

End-of-day quote Korea S.E.
-	-